# Program A15 Blocked Report - Scientific Content Population: Cognitive Enhancers & Dementia-Related Psychopharmacology

## Status

Blocked.

Program A15 was requested for the scientific population of cognitive enhancers and dementia-related psychopharmacology in the Official Scientific Knowledge Base.

This program cannot be executed at this moment because its required upstream dependency, Program A14, is blocked.

## Requested Program

```text
TRACK A - Scientific Knowledge Expansion
PROGRAM A15 - Scientific Content Population: Cognitive Enhancers & Dementia-Related Psychopharmacology
```

## Requested Scope

The requested scope includes:

- donepezil;
- rivastigmine;
- galantamine;
- memantine;
- cholinesterase inhibitor scientific profiles;
- NMDA antagonist scientific profiles;
- cognitive domain mapping;
- behavioral symptom mapping;
- disease stage mapping;
- older adult safety model;
- cardiovascular and neurological safety;
- caregiver considerations;
- dementia stage mapping;
- Knowledge Graph integration;
- Evidence Runtime validation;
- Safety Engine compatibility.

## Block Reason

Program A15 depends on:

- Program A14 - Scientific Content Population: ADHD Medications;
- Program 21 - Scientific Validation Framework;
- Program 22 - Knowledge Governance Platform;
- Safety Engine;
- Evidence Runtime;
- Clinical Operating Mind.

Program A14 is currently blocked by Program A13.

The dependency chain remains blocked back to Program A03:

```text
A15 -> A14 -> A13 -> A12 -> A11 -> A10 -> A09 -> A08 -> A07 -> A06 -> A05 -> A04 -> A03
```

Program A03 is still waiting for:

- official source corpus intake;
- source acquisition matrix completion;
- reviewer assignment;
- field-level traceability validation;
- editorial gate validation;
- Fluoxetine pilot before broader scientific population.

The current authorized next mission remains:

```text
MISSION A03-002 - SSRI Source Corpus Intake
```

## Missions Blocked

The following Program A15 missions are blocked:

- A15-001 - Donepezil Scientific Population;
- A15-002 - Rivastigmine Scientific Population;
- A15-003 - Galantamine Scientific Population;
- A15-004 - Memantine Scientific Population;
- A15-005 - NMDA Mechanism Mapping;
- A15-006 - Combination Therapy Metadata;
- A15-007 - Cognitive Domain Mapping;
- A15-008 - Behavioral Symptom Mapping;
- A15-009 - Disease Stage Mapping;
- A15-010 - Cardiovascular Safety;
- A15-011 - Neurological Safety;
- A15-012 - Older Adult Safety Model;
- A15-013 - Knowledge Graph Integration;
- A15-014 - Evidence Runtime Validation;
- A15-015 - Safety Engine Compatibility;
- A15-016 - Scientific Quality Review;
- A15-017 - Coverage Analysis;
- A15-018 - Consistency Analysis;
- A15-019 - Scientific Audit;
- A15-020 - Replay Support;
- A15-021 - Scientific Trace;
- A15-022 - Scientific Tests;
- A15-023 - Scientific Documentation;
- A15-024 - ADR - Cognitive Enhancers Scientific Population.

## Numbering Conflict Detected

The requested program mentions ADR 0042 for the cognitive enhancers scientific population.

ADR 0042 already exists as:

```text
0042_BLOCK_A14_UNTIL_A13_VALIDATION.md
```

Therefore, this block uses ADR 0043 to preserve sequential ADR numbering and avoid reuse.

## Architectural Risks Avoided

Blocking Program A15 avoids:

- scientific content population without a validated source corpus;
- geriatric and dementia-related medication content without validated field traceability;
- bradycardia, syncope, weight loss, renal and hepatic considerations without validated source governance;
- caregiver and dementia-stage metadata without semantic governance;
- Safety Engine consumption before publication gate;
- Evidence Runtime linkage before source validation;
- premature Clinical Operating Mind integration;
- false impression of readiness for neuropsychiatric or geriatric clinical reasoning;
- accidental creation of treatment recommendation or prescribing logic.

## Prohibited Execution

Until this block is resolved, the following are prohibited:

- populating cognitive enhancer medication scientific fields;
- creating cholinesterase inhibitor or NMDA antagonist profiles;
- creating dementia stage mappings;
- creating cognitive domain mappings;
- creating older adult safety models;
- integrating dementia-related medication content with the Safety Engine;
- integrating dementia-related medication content with the Evidence Runtime;
- publishing cognitive enhancer content into the official knowledge base;
- using dementia-related medication content in clinical reasoning;
- generating treatment recommendations;
- generating prescription-oriented outputs.

## Required Conditions to Unblock

Program A15 can be reconsidered only after:

1. Program A03 completes source corpus intake and editorial validation;
2. Programs A04 through A14 are completed in order, or a formal CTO exception ADR is approved;
3. the scientific population workflow has passed validated medication-class cycles;
4. older adult safety governance is defined;
5. dementia-stage and cognitive-domain semantic governance is defined;
6. caregiver-consideration metadata requirements are validated;
7. Evidence Runtime and Safety Engine compatibility gates are confirmed;
8. NEXT_MISSION is updated by governance to authorize Program A15.

## Files Not Created

No cognitive enhancer scientific profiles were created.

No dementia-related psychopharmacology fields were populated.

No cognitive-domain mappings were created.

No older-adult safety models were created.

No Safety Engine mappings were created.

No Evidence Runtime bindings were created.

No clinical recommendation content was created.

## Decision

Program A15 is formally blocked.

The project must continue from:

```text
MISSION A03-002 - SSRI Source Corpus Intake
```

## Declaration Final

Program A15 cannot execute safely until the upstream scientific population pipeline is validated. The block preserves traceability, semantic governance, clinical safety and the non-prescriptive architecture of PsychRx.
